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1 This consensus statement was developed as an output from the 2016 International Summit on Intellectual 
Disability and Dementia, held in Glasgow, Scotland, 13-14 October 2016, and hosted by the University of 
Stirling and University of the West of Scotland, funded by the RS MacDonald Trust, the Scottish Government, 
and Alzheimer Scotland. Collaborating sponsors included the National Task Group on Intellectual Disabilities 
and Dementia Practices (NTG) in the United States and the University of Illinois at Chicago. The Summit was 
composed of individuals and representatives of many international and national organizations with a stake in 
issues related to adults with intellectual disability affected by dementia. The contents of this statement were 
partially developed under a grant from the United States Department of Health and Human Services, 
Administration for Community Living (ACL), National Institute on Disability, Independent Living, and 
Rehabilitation Research (NIDILRR) Grant # 90RT5020-03-00. However, those contents do not necessarily 
represent the policy of the US Department of Health and Human Services, nor the endorsement by the US 
Federal Government. The opinions expressed represent those of the Summit participants and of the NTG. 
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Abstract 
Objectives: Post diagnostic support (PDS) has varied definitions within mainstream 
dementia services and different health and social care organizations, encompassing a range 
of supports that are offered to adults once diagnosed with dementia until death.   
Method:  
An international summit on intellectual disability and dementia held in Glasgow, Scotland in 
2016 identified how PDS applies to adults with an intellectual disability and dementia. The 
Summit proposed a model that encompassed seven focal areas: post-diagnostic counseling; 
psychological and medical surveillance; periodic reviews and adjustments to the dementia 
care plan; early identification of behaviour and psychological symptoms; reviews of care 
practices and supports for advanced dementia and end of life;  supports to carers/ support 
staff; and evaluation of quality of life. It also explored current practices in providing PDS in 
intellectual disability services.  
Results: The Summit concluded that although there is limited research evidence for 
pharmacological or non-pharmacological interventions for people with intellectual disability 
and dementia, viable resources and guidelines describe practical approaches drawn from 
clinical practice.  Post diagnostic support is essential, and the model components in place 
for the general population, and proposed here for use within the intellectual disability field, 
need to be individualized and adapted to the person’s needs as dementia progresses.   
Conclusions: Recommendations for future research include examining the prevalence and 
nature of behavioral and psychological symptoms (BPSD) in adults with an intellectual 
disability who develop dementia, the effectiveness of different non-pharmacological 
interventions, the interaction between pharmacological and non-pharmacological 
interventions, and the utility of different models of support. 
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Introduction 
Post diagnostic support (PDS) has varied definitions within mainstream dementia services 
and in use by a range of health and social care oriented organizations.  The World Health 
Organization (WHO, 2012) in Dementia, A Public Health Priority, noted that PDS was a 
component of long term care, along with community services and continuing care. The 
WHO defines PDS as “planning for the future; offering support, advice and information as 
needed, and helping maintain independence (p.51).”  The Report also defined community 
services as “helping people with dementia to remain at home as long as they wish and until 
it is no longer possible, and providing short breaks / respite care to support [carers] and 
providing an opportunity for social engagement for the recipient”.  Continuing care was 
defined as “caring for people who can no longer stay at home (e.g. in different kinds of 
supported or institutional living arrangements such as group homes and residential care), 
and providing support for the end stages of dementia. 
 
Other organizations have taken a different perspective and define PDS as generally 
encompassing all activities following diagnosis. Using a conceptual perspective, Alzheimer 
Scotland (2011) published a model built upon five “pillars” to help explain the range of 
services considered useful in post-diagnostic support. The pillars are (a) supporting 
community connections (supports to maintain and develop social networks); (b) peer 
support (derived from other people with dementia, their families, and carers – to help come 
to terms with having dementia and maintain well-being and resilience); (c) planning for 
future care (supports, when they are ready, to plan the shape of their future care from their 
own perspective together with those around them, developing a personal plan with their 
choices, hopes, and aspirations which can guide professionals), (d) understanding the illness 
and managing the symptoms (support to come to terms with dementia and learn about self-
management of the condition); and (e) planning for future decision making including 
addressing other legal issues, such as  setting up ‘powers of attorney’. 
 
Using a psychological perspective, Watts, Cheston, & Moniz-Cook, (2013) suggested a model 
that includes a series of supports, including psychosocial interventions based on the needs 
and preferences of the person with dementia and, where appropriate, his or her carer; 
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giving attention to the cognitive and emotional aspects of dementia; addressing complex 
needs through various means; providing psychosocial interventions for carers of people with 
dementia; ensuring that staff delivering psychosocial interventions are appropriately trained 
and supervised; and obtaining feedback on the efficacy of the interventions.  The British 
Psychological Society Dementia Advisory Group (British Psychological Society, 2016) 
emphasised the importance of focusing care and support on the person rather than the 
disease, leading to an emphasis on what helps people to live well with dementia. They 
recommend that people have the knowledge of where to get what they need; a sense of 
belonging and being valued by their family and community; opportunity to participate in 
meaningful activities, and be part of a local dementia friendly and supportive community; 
have support that enables people to live a full life including the use of life stories, evidence 
based psychological interventions and strategies for maintaining or improving a person’s 
skills, interests and activities; and, live in an enabling and supportive environment. 
 
 
Others have noted that PDS needs to employ varied components to be effective.  The 
components might include (a) conveyance of information to the person diagnosed with 
dementia, as well to his or her potential carers (Abley et al., 2013; Prince, Comas-Herrera, 
Knapp, Guerchet,  & Karagiannidou,  2016); (b) stimulating and aiding in advance care 
planning (Dening, King, Jones, Vickestaff, & Sampson, 2016); (c) continual and multi-layered 
interventions and care supports (Backhouse, Dickens, Richards , McCabe, 2015); (d) 
interventions which are directed at reducing carer burden and supports for carers in 
developing appropriate coping strategies (Dawson, Bowes, Kelly, Velzke, & Ward, 2015; 
WHO, 2015); (e) for some, self-directed care, including adoption of ‘advance directives’ or 
‘advance decisions’ for future care (Dawson et al., 2015; Health Quality Ontario, 2008); and 
(f) mitigating behavioural crises (Kales, Gitlin, & Lyketsos, 2015).  It has been proposed that 
the main objective of PDS is to enable people with dementia to continue living in the 
community with a good quality of life, provide information and support, support people in 
dealing with issues arising from receiving a diagnosis, and delay potential admission to long-
term residential care (Szymczynska, Innes, Forrest, & Stark, 2010).  In summing up a critical 
review of PDS, Dawson et al., (2015), noted that “the best outcomes for people with 
dementia are associated with services that are timely, responsive, flexible, and tailored to 
individual need.” 
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With respect to timelines, initially, PDS referred to the period after diagnosis and through 
the first year (consistent with the WHO, 2012, perspective).  However, increasingly PDS is 
being referred to as appropriate post diagnostic care throughout the rest of the person’s life 
(Department of Health 2016).  This timeline also recognizes the changing demands that 
evolving dementia presents to people, and that PDS in turn changes in focus with 
progression. Therefore, any definition needs to be sufficiently fluid to accommodate varied 
interventions and approaches defined by both the stage of dementia and the needs of the 
person with dementia.  This notion has therefore led to varying perceptions and models of 
PDS. 
 
An issue discussed at the International Summit2 was ‘To what degree and intent does PDS 
with respect to people with intellectual disability mirror these generic models and 
practices?’   For the most part, there is general agreement that within services for people 
with intellectual disability, PDS is aimed toward the person with dementia, their families, 
their friends, and their support staff.  The support may be through specific non-
pharmacological and / or pharmacological approaches and through specialised care 
practices.   
 
The aim of this Summit statement is to explore how PDS for persons with intellectual 
disability corresponds or differs from applications in the general population, and what are 
the critical components that should make up PDS when applied to people with intellectual 
disability. 
The rationale for a consensus statement is based on the need to formalize the sequencing of 
service provision following both suspected and then diagnosis of dementia.  People with 
intellectual disabilities are experiencing increasing life expectancy and reduced morbidity, 
and with this, susceptibility to the same neuropathologies as for people in the general 
population.  The exception to this is people with Down syndrome, where there is well 
                                                            
2 The 33 Summit participants represented a number of disability, aging, and dementia national and 
international organizations, academic institutions, government officials, and family members, had diverse 
professional backgrounds, and came from some 15 countries in Europe and North and South America. 
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documented significant elevated risk of developing Alzheimer’s disease.  The summit 
recognized that there is a need for a statement that can focus attention on PDS processes 
and services as well as stimulating the research agenda and produce new approaches to 
public health policy for people with intellectual disabilities and dementia. 
 
In summary, the literature highlights that approaches in the general population and for 
people with an intellectual disability typically run in parallel, with the exception that in many 
situations the PDS services that are made available to  people with intellectual disability 
tend to be extensions of clinical services that are provided prior to dementia, which are then 
then adapted to the specifics of dementia. This is covered in detail in the Approaches 
section below. 
 
PDS Model with Application to Intellectual Disability 
The Summit explored what might comprise a working model of PDS that could be applied to 
people with intellectual disability and dementia and their carers/ support staff.  Firstly, the 
proposed model’s assumption is that the timeline for PDS is from the point where the 
diagnosis is highly suspected to when the person reaches the end of life stage of dementia.  
End of life issues are considered in a separate publication from the Summit (McCallion et al., 
2017).  Secondly, the model supposes that in concert with national dementia care policies, 
family, ethnic and cultural values, and the preferences of the adult, provision of PDS is 
within a community-based framework. It is therefore designed to preclude inappropriate 
change of accommodation or day services.  The components of the proposed model include: 
• Post-diagnostic counselling/ support and education is offered to the person and 
carers/ support staff to help empower them to deal with the condition in the most 
optimal way related to the diagnosis, its implications, and the probable 
course/trajectory. 
• Psychological and medical surveillance is carried out throughout the course of 
decline to address dementia-related needs and conditions (e.g. epilepsy) and non-
dementia comorbid conditions, irrespective of whether they impact directly on the 
course of dementia. 
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• Periodic, but regular and planned, reviews are undertaken of the person’s program / 
care plan to identify significant changes in health, function and quality of life, and 
adjustments are made in activities and care practices to ensure that the person 
continues to receive quality person-centred care. 
• Early Identification of behavioural and psychological symptoms of dementia occurs 
and reviews of care practices and supports are undertaken when such symptoms are 
present.  
• Reviews are undertaken of care practices and supports provided when advanced 
dementia is reached and when the condition of the individual changes and there is a 
presumption of approaching death. 
• Supports are offered to carers/ support staff throughout the course of the condition, 
from both specialist and mainstream services, and there is a continuing provision of 
information. 
• Quality of life is evaluated at regular intervals from both the perspective of the 
person with intellectual disability and carers/ staff, across the course of the person’s 
journey. 
These components are necessary across all stages of dementia, although some are more 
pertinent to specific stages.  However, it is recognised that excellence in dementia care is 
facilitated by thorough and detailed future planning, so that professionals, carers, and paid 
staff are cognisant of future issues that will arise and have planned for them (e.g. for 
advanced dementia and end of life). 
 
Approaches 
The Summit arrived at consensus in principle that PDS is integral and essential for people 
with intellectual disabilities who develop dementia.  It was acknowledged that most 
prescriptive work with respect to intellectual disability and PDS generally should follow that 
of the precepts for PDS in the general dementia care field.  However, in many situations, 
services for people with intellectual disability are often more focused on taking a person-
centred approach to care and support than those in the general dementia field.   It was clear 
that there are differences in policies and practices in different countries with respect to 
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what constitutes the post-diagnostic period. The Summit agreed that PDS has sequential 
and concurrent features, including what happens early in the post-diagnostic period, what 
follows in general with care directed toward mitigating progressive decline, and how 
ancillary features are supported and augmented.  The Summit also recognized the benefits 
of both non-pharmacology and pharmacological approaches to PDS. 
 
In many economically developed nations where the state funds health and/or welfare 
services, and who have explicit public policy enabling lifelong support services for people 
with an intellectual disability, adults who develop dementia are usually known to formal 
services.  PDS is therefore generally aimed at adapting what is already known about and in 
place for them to meet this added need.  This may entail accessing additional supports both 
for the person and the people supporting him or her at social, emotional, and behavioural 
levels, as well as using specific interventions that have been adapted to accommodate the 
person’s degree of intellectual disability (Tiziano et al., 2017). It is generally recognized that 
levels of function, language skills, and self-direction will define what interventions may be 
most useful. From an evidence-based perspective, as there is not yet a large body of 
research on the efficacy of specific interventions or approaches, most of the knowledge in 
this area is drawn from clinical practice or consensus among knowledgeable workers and 
organizations (BPS, 2015; Dodd, Bush, & Livesey, 2015; Jokinen et al., 2013).  
 
In other countries, or in situations where the adult may have never been part of intellectual 
disability specialty services, this may be handled differently.  At the point of diagnosis, 
recognition that dementia is present may begin the introduction of supports that may be 
similar to those provided to other people with dementia, but the process may lack formality 
and be offered on an ad hoc basis.   Brazilian public policy, for example, supports adults with 
Down syndrome typically living with their families; rather than being in residential or long 
term supported living, or institutional care (Fonseca, de Oliveira, de Figueiredo Ferreira 
Guilhoto, Cavalheiro, & Bottino, 2014).  Voluntary carers, usually parents or siblings and at 
times a neighbour or friend, prevail over professional carers. In such situations, it is common 
for family members, despite often aging or at times having other caring commitments 
themselves, to become carers due to the fear that the person with intellectual disability 
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might be neglected in an institution (Carvalho, Ardore, & Castro, 2015).   However, if 
support has not been typically accessed or required until this point, the changes in their 
family member can prove challenging for the family and at times result in a breakdown in 
living arrangements. This places the person with intellectual disability at increased risk of a 
crisis rather than planned move, often with associated behavioural changes due to a new 
and strange environment with different carers or admission to a long-term care facility 
(Carvalho et al., 2015; Courtenay, Jokinen, & Strydom, 2010). 
   
It is the Summit’s position that irrespective of the nature and extent of existing public 
policies or services available within a country, special efforts be made to aid the family or 
other carers to have an understanding of dementia and its consequences, as well as to offer 
information, aid, and supports for extended caregiving, and provide relief for caregiving 
when indicated.  Such PDS-related activities can be undertaken via formal initiatives or via 
informal efforts of non-governmental organizations, parent associations, or by neighbors 
and friends.  For those nations with undeveloped market economies and low levels of 
investment in health and welfare services where there is an absence of focus on dementia 
supports for people in general, and for people with intellectual disability in particular, this 
Consensus statement can be adopted and used to help develop the required supports in the 
future.  
Non-pharmacological approaches 
Non-pharmacological approaches have been shown to be useful, versatile, and cost-
effective in improving outcomes and quality of life among adults with dementia (Olazaran et 
al., 2010).  These approaches should also enhance the quality of life of persons with 
intellectual disability affected by dementia, be used in combination as needed for each 
person, and be able to demonstrate effectiveness (Dodd et al., 2015; Gitlin, Kales, & 
Lyketsos, 2012).  All approaches and practices should be subject to periodic and regular 
review as outlined in our model of the components of PDS. 
 
Early phase PDS and intellectual disability.  PDS should start with sharing the diagnosis of 
dementia with the person with intellectual disability wherever possible; although there are 
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differing opinions about the utility of doing this (BPS 2015; Tuffrey-Wijne & Watchman, 
2014).  The presentation of information and how it is delivered will be a function of the 
innate capacity of the adult to integrate the information and how cognitively affected he or 
she may be by dementia.  Many professionals believe that an individualised person-centred 
approach to deciding how much information to share with the person with intellectual 
disability and their carers and support staff is key to enabling adaptation and understanding 
of what the person, their carers and support staff are experiencing and will continue to 
experience.  This will enable adults to better understand and cope with their changing 
experiences (Tuffrey-Wijne & Watchman, 2014; Watchman, 2012). This approach also helps 
to ensure that the person is involved as much as possible in decisions about support and 
care, and is supported in describing and recording his or her views and preferences about 
future care.  Technical aids that can build capability among carers / support staff have been 
developed and can be used with people, carers and support staff, such as “The Journey of 
Life, About My Friend and About Dementia” (Dodd, Turk, & Christmas, 2005 a -c), “What is 
Dementia?” (Kerr & Innes, 2000), and “Jenny’s Diary” (Watchman, Tuffrey-Wijne, & Quinn, 
2015) in the UK, “Guidelines for Structuring Community Care and Supports for People with 
Intellectual Disabilities Affected by Dementia“ (Jokinen et al., 2013) in the USA,  “Menschen 
mit Demenz und geistiger Behinderung begleiten- eine Handreichung für Mitarbeitende der 
Behinderten- und Altenhilfe“ (Demenz-Service NRW, 2016) in Germany, and “Dementie bij 
mensen met een verstandelijke handicap:  brochure voor verwanten en professionele 
ondersteuners” (Maaskant & Schuurman, 2012) in the Netherlands. 
 
Psychological and non-pharmacological approaches for people with intellectual disability 
and dementia need to be delivered in line with a clear conceptual framework of dementia 
that aids staff in understanding what is happening to the person with dementia and the 
effect of their care and responses (BPS, 2015).  Current guidelines for the management of 
behavioral and psychological symptoms of dementia in the general population include those 
from the UK National Institute for Health and Care Excellence (NICE, 2012), the American 
Psychiatric Association (2013), the International Psychogeriatric Association (2015), the 
German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN, 2016), the 
Dutch Society for Clinical Geriatrics (Nederlandse Vereniging voor Klinische Geriatrie, 2014) 
and the American Geriatrics Society (2013).  With respect to PDS, these guidelines 
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recommend the use of non-pharmacologic behavioral strategies at first for behavioural 
problems, but do not present any evidence base for these approaches or give weight to the 
evidence for one non-pharmacologic approach over another (Kales et al., 2015). 
 
Mid-stage progressive and decline support features.  Often the most commonly used 
approaches for people with intellectual disability are the same as those used in the general 
population, but may need adaptation.  These include developing an understanding of 
dementia (Buijssen, 2005); anxiety and stress reduction (Dodd, 2010); life story work 
(Gibson, 1994); reminiscence, (Pinquart & Forstmeier, 2012), reality orientation and 
validation techniques (Kerr, 2007); and helping peers to understand dementia (Dodd et al., 
2005a-c).  These techniques can have a fruitful effect on cognitive capacity, depression, and 
quality of life (Pinquart & Forstmeier, 2012).  A range of other therapeutic approaches also 
may be effective with people with intellectual disability and dementia, including music 
therapy (Ueda, Suzukamo, Sato, & Izum, 2013), aromatherapy, sensory stimulation 
(including Snoezelen), touch, and the use of electronic devices, domotica (smart homes), 
and entertainment.  There is further information regarding specific activities and 
interventions for different stages of dementia from Kalsy–Lillico (2014). 
The interventions will be consistent with those used generally by intellectual disability 
professionals, where the emphasis is on a person-centered approach with interdisciplinary 
and multiagency working.  These will include the provision of accurate and timely 
information; formulation; interventions to maximise and maintain independence, skills and 
health; and at the same time promoting safety comfort, and dignity.  Reducing excessive 
demands and simplifying routines are is important, while minimising avoidable changes, 
especially any exclusion from appropriate health and social care services. The assumption is 
that when an adult is in an unsuitable environment for his or her needs (e.g., the physical 
environment places the person at risk, the person is isolated or bullied) and may be 
depressed, a change of environments may be beneficial (Gaertner, 2016). Furthermore, 
awareness needs to be maintained regarding the person’s changing needs and interventions 
need to be reviewed at regular intervals.  
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Focus on programmatic processes 
Provision of supportive environments can be engineered so that people with dementia can 
remain in the family home, if the home is suitable as a care setting and this is wanted by the 
person with intellectual disability.  Supports in such situations would entail providers 
working closely with family carers to sustain their efforts at providing supervision and basic 
personal supports, as well as dementia-proofing their home (when that is needed) and 
teaching techniques to address behaviour.  Also, when home-based caregiving is not viable 
or the person’s care needs have exceeded the capacity of family carers, then alternatives for 
housing should be made available and anticipated to allow a planned process.  Such 
alternatives may include small group homes, preferably those that are dementia-capable 
and have sufficient staffing to provide extended care as dementia progresses including 
night-time care.  These alternatives may also need additional support to provide dementia 
suitable physical and social environments (BPS, 2015).  Examples of such community based 
dementia group homes are becoming more prevalent and proving to be suitable alternative 
care environments (Janicki, 2015; National Institute on Aging, 2013; Van Zadelhoff, Verbeek, 
Widdershoven, van Rossum, & Abma T. 2011; Wilson, Malmberg, & Zarit, 1993).  Quality of 
care in such settings has been discussed by Watchman (2012), Janicki, Dalton, McCallion, & 
Zendell, (2005) and Janicki (2011).  Janicki noted that the elements of homes demonstrating 
quality include clinically relevant early and periodic assessment; functional modifications in 
the living setting; staff education for stage-adapted care; and flexible long-term services 
provision that recognises and plans for progression of decline and loss of function. 
 
Environmental adaptations are also now seen as important interventions for effective 
dementia care (Canadian Psychological Association, 2014; De Vreese et al., 2012; Kerr, 
2007), as one of the initial line of intervention before treatment using medication for 
behavioural problems.  Dementia enabled designs, explored further in Gaertner (2016), 
Jokinen et al., (2013), and McCarron, McCallion, Reilly, & Mulryan, (2014), may result in 
fewer falls, decrease in stress, confusion, and anxiety and could lead to a reduction in the 
use of anti-psychotics and need for sedation.  They also can increase quality of care, as staff 
are usually trained to understand and provide supports for people with dementia, and the 
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environments generally are adapted to enable residents to be as autonomous as they can 
be. 
 
Focus on individualized interventions   
As dementia progresses, people become less able to instigate meaningful activities.  This 
does not necessarily mean that they do not want to engage in activities, only that at times 
they can no longer initiate them themselves.  There is evidence from clinical practice that 
giving people meaningful, but failure-free, activities can reduce stress and adverse 
behaviours and encourage a sense of well-being, accomplishment and improved mood. 
Failure-free activities need to be appropriate to the individual (Sheridan, 1997), and should 
include a range of involvements that engage the adults in easy tasks where success is 
optimized, such as looking at magazines, carers sitting with the person describing what is 
happening outside, talking about a favourite object, or going for a walk (BPS, 2015; Kalsy-
Lillico, 2014). 
  
BPSD:  Consideration also needs to be given to behavioural and psychological symptoms of 
dementia (BPSD) which is a description used typically more with people with dementia 
within the general population than in services for people within intellectual disability 
services.  BPSD may include agitation, aberrant motor behaviour, anxiety, elation, irritability, 
depression, apathy, disinhibition, delusions, hallucinations, and sleep or appetite changes, 
which are present at one time or another in the  majority of adults affected by dementia 
(Devshi et al., 2015; Kales et al., 2015; Purandare, Allen, & Burns, 2000). BPSD may be more 
commonly associated with dementia in individuals with Down syndrome, and is often 
observed even before the clinical dementia diagnosis is made (Dekker et al., 2015).  
Accurate recognition of BPSD may increase awareness and understanding of behavioural 
and psychological issues, thus enabling adaptive caregiving and provision of appropriate 
interventions. 
 
14 
Although closely associated with an advancing dementia, BPSD may be caused by factors 
other than the dementia.  In particular, people with dementia may have a range of 
comorbid conditions that are overlooked through diagnostic overshadowing (BPS, 2015).  
Carers and support staff may fail to recognise that the person with dementia is experiencing 
pain and offer timely treatment, with symptoms presenting as BPSD (BPS, 2015).  People 
with intellectual disabilities and dementia may experience sleep disturbance, hyperactivity 
(including agitation and aggression), affective symptoms (such as anxiety and depression), 
and delusions and hallucinations.  Given that various stimuli may set-off an incident of such 
changed behaviour, it is important to continue to assess all physical and psychological 
causes. It has been suggested that a combination of non-pharmacological and careful use of 
pharmacological interventions can help in the therapeutic managing of BPSD (Cerejeira, 
Lagarto, & Mukaetova-Ladinska, 2012), German Association for Psychiatry, Psychotherapy 
and Psychosomatics (DGPPN), 2016)).   
 
Behaviour Management:  Behaviour management therapies, and carer and residential staff 
education appear to have lasting effectiveness in the management of BPSD (Livingston et 
al., 2005), while sensory interventions, and music therapy may have short-term effects. 
Behavioural approaches in the general population recognise the importance of that people 
may not be having their needs met and the need to manage underlying causes, including 
discomfort, loneliness, and anxiety (Cohen-Mansfield, Dakheel-Ali, Marx, Thein, & Regier 
2015). Positive behaviour support approaches have become established as a preferred 
approach in the UK when working with people with intellectual disability who present 
behaviours that can be perceived as challenging (BPS, 2015; Department of Health, 2014; 
Gore et al.,2013; Royal College of Psychiatrists, 2007), and have been proposed for use with 
persons with dementia.  Positive behaviour support emphasizes person-centred values, 
aims to enhance community presence, increases personal skills and competence, and 
ensures dignity and respect is maintained for the person being supported (Dodd, Turk, & 
Christmas, 2009). Although there is very limited research evidence supporting its use in 
older people with intellectual disability and dementia (Fonseca et al., 2015), it is increasingly 
being used in clinical practice. In general, when a diagnosis of dementia is suspected a shift 
in value from increasing skills to maintaining skills and accepting decreasing skills can be 
helpful in terms of reducing stress of the individual. Such applications of behaviour-analytic 
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approaches examine the environmental factors that may influence the frequency and 
intensity of dementia symptoms and the identification of contingencies that aid in 
individualized care planning and that decrease excess behaviours in older adults with 
dementia (Trahan, Kahng, Fisher, & Hausman, 2011).  It is not known how these techniques 
affect the generalization or maintenance of behaviour change, which is particularly 
important given that individuals with dementia demonstrate deterioration in skills over 
time.  
 
In all cases where there is behaviour that challenges other people, the standards of 
assessment of the behaviour and subsequent intervention should occur as outlined in 
guidance, such as “Challenging behaviour: a unified approach” (Royal College of 
Psychiatrists, 2007) and its update  (Royal College of Psychiatrists, 2016).  This includes 
ensuring that any intervention addresses the person, the environment, and the interaction 
between the two.  
 
Environment:  Finally, environmental adaptations are now considered an important 
intervention for dementia (Canadian Psychological Association, 2014; De Vreese et al., 2012; 
Kerr, 2007), as one of the initial line of interventions before treatment using medication for 
behavioural problems.  Dementia enabled design, explored further in Gaertner (2016) and 
Jokinen et al., (2013), may result in decreases in falls, and decreases in stress, confusion and 
anxiety and can lead to a reduction in the use of anti-psychotics and need for sedation. 
 
By understanding dementia, adopting a clear philosophy of care which includes a flexible 
and person-centred approach, tailoring interventions to the needs of the person and the 
stage of dementia, and using the whole range of psychological and non-pharmacological 
interventions, the quality of life for the person with intellectual disability and dementia, 
their peers, staff and carers can be maintained so that the person leads a fulfilling life.   
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Later stage supports.  Eventually decline will compromise cognitive and physical function, 
and be associated with bodily system failures, leading to a progression of gross dysfunction 
and death.  During this stage, often PDS take on different features, with interventions 
focusing on maintenance of bodily functions, maintaining comfort, and the provision of 
palliative care (see McCallion et al., 2017; Service et al., 2017).  In particular, issues related 
to dysphagia become paramount, with difficult decisions needing to be made on whether 
the person should be ‘eating at risk’ when the person presents with unavoidable risk of 
aspiration (DGPPN, 2016, p.96-97). It is recognized that end-of-life care and related support 
considerations come into play among these individuals when most are in the advanced 
stage of dementia (McCallion et al., 2017).  End stage PDS generally encompasses 
determining whether advanced dementia is present, proposing use of palliative care 
services (including hospice), integrating efforts between intellectual disability and palliative 
care providers, and offering specialized aid to family carers, and training for paid carers on 
end-of-life care and supports. 
 
Pharmacological interventions 
The two major classes of medications to reduce the cognitive symptoms of dementia are 
acetylcholinesterase inhibitors (AIs), such as donepezil, which increase central acetylcholine 
concentration, and an N-methyl-D-aspartate (NMDA) antagonist (such as memantine).  
Neither are believed to have disease-modifying properties and are therefore not used to 
prevent the long-term histopathological progression of disease. However, in the short to 
medium term, they have been shown to slow clinical deterioration, and there is a strong 
evidence-base for their use in the general population. Furthermore, recent evidence 
suggests that continuation of acetylcholine esterase inhibitors particularly donepezil, even 
in those with more severe dementia, resulted in better cognitive outcomes compared to 
stopping the medication (Howard et al., 2012) and delayed admission to nursing homes 
(Howard et al., 2015). These drugs are therefore recommended for treatment of dementia, 
particularly Alzheimer’s disease, through guidance from the US (National Institute on Aging, 
2016; Moran, Rafii, Keller, Singh, & Janicki, 2013) and in the UK (NICE, 2012).  These 
guidelines explicitly include individuals with intellectual disability and Down syndrome in 
their recommendations.  The NICE guidance states that ‘the difficulty in staging dementia by 
17 
using the MMSE, in people with intellectual disabilities should not disadvantage them, thus 
introducing some flexibility for prescribers.’ 
 
Most research into Alzheimer’s disease in people with intellectual disability has been with 
individuals with Down’s syndrome due to their neuropathological association with the risk 
of developing an Alzheimer-like dementia (Wiseman et al., 2015). Acetylcholine esterase 
inhibitors are the most commonly prescribed anti-dementia medications in this population. 
A review of the literature found a few small controlled studies confirm that donepezil and 
rivastigmine are well tolerated in the people with Down’s syndrome (Eady, Courtenay,  & 
Strydom, 2015; Prasher, 2004). These studies have some methodological flaws, including 
small sample size, choice of controls, and length of follow-up. Other than commenting on 
safety and the side effect profile, it is therefore not possible to draw firm conclusions on the 
efficacy of acetylcholine esterase inhibitors on cognition or functioning, or the control of 
associated behavioural and psychiatric symptoms in people with Down syndrome and 
dementia (Strydom et al., 2009). There is however some evidence that these treatments 
may reverse or delay the symptoms of dementia during the early and middle stages of 
dementia (Lott, Osann, Doran, & Nelson, 2002). Further evidence is required, including from 
non-randomized designs, as it may not be possible to complete further randomized control 
studies (Glover, Bernard, Branford, Holland, & Strydom, 2014). In contrast, a recent 
prospective double-blind, randomized control trial compared memantine with placebo in 
people with Down syndrome and concluded that memantine is not effective for the 
treatment of dementia in this population (Hanney et al., 2012).  A major trial of vitamin E for 
dementia in Down syndrome has also demonstrated a lack of efficacy (Sano et al., 2016). 
 
A 2015 Cochrane review of medication for dementia in people with Down syndrome 
(Livingstone, Hanratty, McShane, & Macdonald, 2015) concluded that overall, the quality of 
evidence is low which prevents firm conclusions to be made and the authors argued for 
further trials. However, it is probably unlikely to conduct trials based on withholding 
treatments (in a placebo arm) from individuals with dementia if those treatments are 
accepted practice and recommended by current guidance.  Although evidence for the use of 
18 
medication is lacking, current clinical consensus is that it should not be stopped if it is 
beneficial for an individual with intellectual disability and dementia. 
 
Pharmacological management of behavioural issues in people with intellectual disability are 
discussed in BPS (2015), Eady et al., (2015), and Sheehan et al., (2015). In summary, the use 
of psychotropic drugs (especially antipsychotics) or sedatives for people with intellectual 
disability and behavioural problems remain controversial, particularly in older adults with 
dementia, and current guidelines (BPS, 2015; American Psychiatric Association, 2016) are to 
use alternative treatments such as psychological, therapeutic and behavioural interventions 
as first-line options, but in specific situations medication can be considered (e.g., presence 
of specific distressing symptoms such as hallucinations and serious sleep problems). If 
psychotropic drugs are used, they should be carefully monitored and used for short periods. 
A general principle is that medication treatment for psychiatric disorders in older people 
with intellectual disability should be started at low dosages and be increased cautiously 
while monitoring response and side-effects (Eady et al., 2015). Older adults with intellectual 
disability are at risk of polypharmacy (American Psychiatric Association, 2016), and older 
age may be a risk factor for development of side effects. 
 
Commentary 
 
The Summit together with Shakespeare, Zeilig & Mittler (2017) believe that this Consensus 
Statement is consistent with the Convention on the rights of persons with disabilities, and 
that the convention does include consideration of dementia.  The Convention on the Rights 
of Persons with disabilities was adopted in 2008, and represented a paradigm shift from a 
medical model of disability to a social model for people recognized as having a disability.  
However, there is little evidence that persons with dementia are being included in its 
implementation at national level.  The Summit (Watchman et al., 2017) recommended that 
a human rights approach be adopted that ensures  that: everyone with dementia including 
people with intellectual disability, are provided with information in an accessible format to 
make people aware of their rights;  intellectual disability organizations respond to a call for 
greater advocacy on behalf of their members with an intellectual disability and dementia 
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and liaise with dementia organizations to share an advocacy role for families; that all 
nations review laws and policies to replace regimes of substitute decision-making by 
supported decision-making, which respects the person’s autonomy, will and preferences;  
deinstitutionalization should be achieved and legal capacity must be restored to all persons 
with intellectual disabilities, who must be able to choose where and with whom to live. 
 
The Summit believes that what follows the diagnosis of dementia among adults with 
intellectual disability forms a phase of life that requires special attention from providers, 
clinicians, and carers.  It is noted that in many countries most people with intellectual 
disability who develop dementia are usually known to services; thus, the Summit believes 
that PDS should be aimed at adapting what is already known about and in place for the 
person and in accessing additional supports to meet their changing needs. The Summit also 
recognised that while some countries already have in place policies, strategies, and formal 
support systems to support people with intellectual disabilities and dementia, in other 
countries it is acknowledged that such supports may be absent or only rudimentary and 
thus believes that support need to be developed and delivered by a range of non-
governmental, family and self-help organisations.  The key is that some degree of support 
needs to be available to aid the person with an intellectual disability with dementia and 
their immediate carers and /or support staff. 
 
The Summit also believes that on a structural level, the effectiveness of PDS applications to 
adults with intellectual disability need to be fully evaluated in more complex environments 
to ensure that interventions and care practices undertaken have a positive effect on the 
person’s quality of life.  The support may be through specific non-pharmacological and / or 
pharmacological approaches and stage-adapted changes in care practices.  Further, as what 
constitutes an appropriate intervention will change as dementia advances, so it will need to 
be individualised to the stage-associated ability and to the changing needs of the person.  In 
addition, the timeline for PDS needs to be acknowledged as the period from the moment of 
diagnosis of dementia through to the end of the person’s life.  The model we have laid out 
should serve as a starting point for effective designs and efforts. 
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Overall, the Summit recognises that there is limited research evidence for interventions 
(whether pharmacological or non-pharmacological) for people with intellectual disability 
and dementia; however, there are a range of resources and guidelines that describe these 
approaches drawn from clinical practice.  Ongoing post diagnostic support is essential, and 
the model components, as in place for the general population, and proposed for use within 
the intellectual disability field, need to be individualised and adapted to each person’s 
needs as the neuropathology and resultant dementia progresses.  Given this, the Summit’s 
position is consistent with other organizations as recognizing PDS as a necessary ingredient 
in care among those individuals with intellectual disability affected by dementia.   
Lastly, the Summit recognises the importance of addressing the process of PDS and believes 
that this Consensus Statement might be useful to clinicians, providers, and national 
organizations, in both planning for people with intellectual disability as they age and 
develop neuropathologies and in adapting services to include more focus on geriatric and 
gerontological issues in general, and dementia related care in particular. 
Recommendations for future research: 
The Summit recommends that research into the areas outlined below is commissioned and 
undertaken 
1. The prevalence and nature of BPSDs in adults with intellectual disability who develop 
dementia, and whether there is a difference in prevalence and nature related to the 
cause of the person’s intellectual disability or by the type of dementia. 
2. The effectiveness of non-pharmacological interventions both individually and in 
combination for symptoms of dementia and for quality of life for people with 
intellectual disability and dementia.  
 
3. The interaction between the use of medications and non-pharmacological 
interventions in reducing BPSD and improving quality of life. 
 
4. The effect on carers and support staff of different models of support looking at issues 
such as resilience, emotional labour, and staff turnover. 
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